U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H28N4O6
Molecular Weight 444.4818
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MITOXANTRONE

SMILES

c1cc(c2c(c1NCCNCCO)C(=O)c3c(ccc(c3C2=O)O)O)NCCNCCO

InChI

InChIKey=KKZJGLLVHKMTCM-UHFFFAOYSA-N
InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2

HIDE SMILES / InChI

Molecular Formula C22H28N4O6
Molecular Weight 444.4818
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.

CNS Activity

Curator's Comment:: Mitoxantrone does not cross the blood-brain barrier to any appreciable extent.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NOVANTRONE

Approved Use

Mitoxantrone injection USP (concentrate) is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone injection USP (concentrate) is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone injection USP (concentrate) in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone injection USP (concentrate) in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.

Launch Date

567216000000
Primary
NOVANTRONE

Approved Use

NOVANTRONE is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). NOVANTRONE is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. NOVANTRONE in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. NOVANTRONE in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.

Launch Date

567216000000
Primary
NOVANTRONE

Approved Use

NOVANTRONE is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). NOVANTRONE is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. NOVANTRONE in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. NOVANTRONE in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.

Launch Date

567216000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.429 mg/L
90 mg/m² single, intravenous
dose: 90 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MITOXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.195 mg × h/L
90 mg/m² single, intravenous
dose: 90 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MITOXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1922 ng × h/mL
40 mg/m² single, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MITOXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.26 μg × h/mL
12 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 12 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
MITOXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
37.1 h
40 mg/m² single, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MITOXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
19.83 h
12 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 12 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
MITOXANTRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
22%
MITOXANTRONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
39 mg/m2 1 times / 4 weeks multiple, intravenous
Highest studied dose
Dose: 39 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 39 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
DLT: Granulocytopenia...
Other AEs: Thrombocytopenia, Nausea and vomiting...
Dose limiting toxicities:
Granulocytopenia (grade 4, 11 patient)
Other AEs:
Thrombocytopenia (grade 3, 11 patient)
Nausea and vomiting (grade 1-2, 9 patients)
Stomatitis (grade 1-3, 6 patients)
Alopecia (grade 1-3, 5 patients)
Diarrhea (grade 1-2, 3 patients)
Sources:
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Disc. AE: Urinary tract infection, Leukopenia...
Other AEs: Nausea, Alopecia...
AEs leading to
discontinuation/dose reduction:
Urinary tract infection (32%)
Leukopenia (19%)
Depression (1 patient)
Left ventricular dysfunction (1 patient)
Bone pain (1 patient)
Emesis (1 patient)
Renal failure (1 patient)
Other AEs:
Nausea (76%)
Alopecia (61%)
Menstrual disorder (61%)
Amenorrhea (43%)
Upper respiratory tract infection (53%)
Stomatitis (19%)
Arrhythmia (18%)
Diarrhea (16%)
Urine abnormal (11%)
ECG abnormal (11%)
Constipation (10%)
Back pain (8%)
Sinusitis (6%)
Headache (6%)
Gamma-GT increased (15%)
SGOT increased (8%)
Granulocytopenia (6%)
Anemia (6%)
SGPT increased (5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea grade 1-2, 3 patients
39 mg/m2 1 times / 4 weeks multiple, intravenous
Highest studied dose
Dose: 39 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 39 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Nausea and vomiting grade 1-2, 9 patients
39 mg/m2 1 times / 4 weeks multiple, intravenous
Highest studied dose
Dose: 39 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 39 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Alopecia grade 1-3, 5 patients
39 mg/m2 1 times / 4 weeks multiple, intravenous
Highest studied dose
Dose: 39 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 39 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Stomatitis grade 1-3, 6 patients
39 mg/m2 1 times / 4 weeks multiple, intravenous
Highest studied dose
Dose: 39 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 39 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Thrombocytopenia grade 3, 11 patient
39 mg/m2 1 times / 4 weeks multiple, intravenous
Highest studied dose
Dose: 39 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 39 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Granulocytopenia grade 4, 11 patient
DLT
39 mg/m2 1 times / 4 weeks multiple, intravenous
Highest studied dose
Dose: 39 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 39 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Bone pain 1 patient
Disc. AE
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Depression 1 patient
Disc. AE
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Emesis 1 patient
Disc. AE
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Left ventricular dysfunction 1 patient
Disc. AE
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Renal failure 1 patient
Disc. AE
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Constipation 10%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
ECG abnormal 11%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Urine abnormal 11%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Gamma-GT increased 15%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Diarrhea 16%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Arrhythmia 18%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Stomatitis 19%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Leukopenia 19%
Disc. AE
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Urinary tract infection 32%
Disc. AE
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Amenorrhea 43%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
SGPT increased 5%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Upper respiratory tract infection 53%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Anemia 6%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Granulocytopenia 6%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Headache 6%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Sinusitis 6%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Alopecia 61%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Menstrual disorder 61%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Nausea 76%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Back pain 8%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
SGOT increased 8%
12 mg/m2 1 times / 3 months multiple, intravenous
Recommended
Dose: 12 mg/m2, 1 times / 3 months
Route: intravenous
Route: multiple
Dose: 12 mg/m2, 1 times / 3 months
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
weak [Ki 85 uM]
weak
weak
yes [IC50 3.39 uM]
yes
yes
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
A systematic overview of chemotherapy effects in acute myeloid leukaemia.
2001
Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
2001
Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.
2001
The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma.
2001
Progressing prostate carcinoma.
2001
Applications of microarray technology in breast cancer research.
2001
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
2001
HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.
2001 Apr
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
2001 Apr
High remission rate in acute myeloblastic leukemia with only two days of chemotherapy.
2001 Apr
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.
2001 Apr
Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness.
2001 Apr
Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
2001 Apr
HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: an isolated instance or a trend?
2001 Apr
Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
2001 Apr 1
Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP).
2001 Aug
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study.
2001 Aug
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
2001 Aug 1
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.
2001 Aug 1
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
2001 Aug 15
Multiple sclerosis treatment 2001.
2001 Feb
Docetaxel in prostate cancer.
2001 Feb
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
2001 Feb
A 20-year experience on malignant lymphomas in patients aged 70 and older at a single institute.
2001 Feb
Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.
2001 Feb 1
Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma.
2001 Jan
Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
2001 Jan
Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.
2001 Jan
Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin.
2001 Jan
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
2001 Jan
Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: cytogenetic and molecular features.
2001 Jan
Detection of human herpesvirus 6 and JC virus in progressive multifocal leukoencephalopathy complicating follicular lymphoma.
2001 Jul
Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.
2001 Jul 6
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
2001 Jun
[Chemotherapy in gastroenterologic neuroendocrine tumors].
2001 Jun
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
2001 Jun
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
2001 Jun
Heterogeneity of proteinkinase C activity and PKC-zeta expression in clinical breast carcinomas.
2001 Mar
Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients.
2001 Mar
Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.
2001 Mar
Primary low-grade B cell non-Hodgkin's lymphoma of MALT type simultaneously arising in the colon and in the lung: report of a case.
2001 Mar
Intensive postremission chemotherapy in Taiwanese adults with acute myelogenous leukemia.
2001 Mar-Apr
Clinical assessment of a chemosensitivity assay as a treatment planning tool for dogs with cancer.
2001 Mar-Apr
Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.
2001 May
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.
2001 May
Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study.
2001 May
Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study.
2001 May
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.
2001 May 1
Cytosine methylation enhances mitoxantrone-DNA adduct formation at CpG dinucleotides.
2001 May 11
Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.
2001 May 15
Patents

Sample Use Guides

The recommended dosage of NOVANTRONE (Mitoxantrone) is 12 mg/m2
Route of Administration: Intravenous
In Vitro Use Guide
Treatment of B-CLL cells for 48 h with mitoxantrone (0.5 ug/ml) induced a decrease in cell viability as determined by MTT assay.
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:38:05 UTC 2021
Edited
by admin
on Sat Jun 26 09:38:05 UTC 2021
Record UNII
BZ114NVM5P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MITOXANTRONE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
MITOXANTRONE [INN]
Common Name English
NSC-279836
Code English
MITOXANTRONE [IARC]
Common Name English
MITOXANTRONE [WHO-DD]
Common Name English
MITOXANTRONE [VANDF]
Common Name English
MISOSTOL
Brand Name English
MITOXANTRONE [MI]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 128499
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
NCI_THESAURUS C253
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
FDA ORPHAN DRUG 125199
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
WHO-ATC L01DB07
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
NDF-RT N0000000176
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
NDF-RT N0000175609
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
LIVERTOX 648
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
WHO-VATC QL01DB07
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
FDA ORPHAN DRUG 96696
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
Code System Code Type Description
MESH
D008942
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
INN
4922
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
FDA UNII
BZ114NVM5P
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
ChEMBL
CHEMBL58
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
WIKIPEDIA
MITOXANTRONE
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
CAS
65271-80-9
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
PUBCHEM
4212
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
EPA CompTox
65271-80-9
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
RXCUI
7005
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C62050
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
DRUG BANK
DB01204
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
EVMPD
SUB09012MIG
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
IUPHAR
7242
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
LACTMED
Mitoxantrone
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
MERCK INDEX
M7572
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
1821
Created by admin on Sat Jun 26 09:38:06 UTC 2021 , Edited by admin on Sat Jun 26 09:38:06 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY